Literature DB >> 17828721

Design, synthesis, and biological properties of highly potent tubulysin D analogues.

Andrew W Patterson1, Hillary M Peltier, Florenz Sasse, Jonathan A Ellman.   

Abstract

Ten analogues of tubulysin D were synthesized and assayed against established mammalian cell lines, including cancer cells measuring inhibition of cell growth by an MTT assay. These experiments establish for the first time the essential features for the potent cytotoxicity of tubulysin D. The activities of analogues 2 to 5 demonstrate that numerous modifications may be introduced at the C-terminus of the natural product with only modest loss in activity, while the activities of analogues 6 to 8 suggest that a basic amine must be present at the N-terminus to maintain activity. Most surprisingly, analogue 10 establishes that replacement of the chemically labile O-acyl N,O-acetal with the stable N-methyl group results in almost no loss in activity. In aggregate, these structure-activity relationships enable the design of analogues such as 11 that are smaller and considerably more stable than tubulysin D but that maintain most of its potent cell-growth inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17828721     DOI: 10.1002/chem.200701057

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  10 in total

1.  Chemotherapeutic evaluation of a synthetic tubulysin analogue-dendrimer conjugate in c26 tumor bearing mice.

Authors:  William C Floyd; Gopal K Datta; Shinichi Imamura; Heidi M Kieler-Ferguson; Katherine Jerger; Andrew W Patterson; Megan E Fox; Francis C Szoka; Jean M J Fréchet; Jonathan A Ellman
Journal:  ChemMedChem       Date:  2011-01-03       Impact factor: 3.466

2.  A road less traveled by: exploring a decade of Ellman chemistry.

Authors:  Anang A Shelat; R Kiplin Guy
Journal:  Bioorg Med Chem       Date:  2008-03-04       Impact factor: 3.641

3.  Structural convergence for tubulin binding of CPAP and vinca domain microtubule inhibitors.

Authors:  Valérie Campanacci; Agathe Urvoas; Liza Ammar Khodja; Magali Aumont-Nicaise; Magali Noiray; Sylvie Lachkar; Patrick A Curmi; Philippe Minard; Benoît Gigant
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-04       Impact factor: 12.779

4.  Total synthesis and biological evaluation of tubulysin U, tubulysin V, and their analogues.

Authors:  Ranganathan Balasubramanian; Bhooma Raghavan; Adrian Begaye; Dan L Sackett; Robert A Fecik
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

5.  Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors.

Authors:  Leanna R Staben; Shang-Fan Yu; Jinhua Chen; Gang Yan; Zijin Xu; Geoffrey Del Rosario; Jeffrey T Lau; Luna Liu; Jun Guo; Bing Zheng; Josefa Dela Cruz-Chuh; Byoung-Chul Lee; Rachana Ohri; Wenwen Cai; Hongxiang Zhou; Katherine R Kozak; Keyang Xu; Gail D Lewis Phillips; Jiawei Lu; John Wai; Andrew G Polson; Thomas H Pillow
Journal:  ACS Med Chem Lett       Date:  2017-09-05       Impact factor: 4.345

6.  Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism.

Authors:  L Nathan Tumey; Carolyn A Leverett; Beth Vetelino; Fengping Li; Brian Rago; Xiaogang Han; Frank Loganzo; Sylvia Musto; Guoyun Bai; Sai Chetan K Sukuru; Edmund I Graziani; Sujiet Puthenveetil; Jeffrey Casavant; Anokha Ratnayake; Kimberly Marquette; Sarah Hudson; Venkata Ramana Doppalapudi; Joseph Stock; Lioudmila Tchistiakova; Andrew J Bessire; Tracey Clark; Judy Lucas; Christine Hosselet; Christopher J O'Donnell; Chakrapani Subramanyam
Journal:  ACS Med Chem Lett       Date:  2016-06-22       Impact factor: 4.345

7.  Asymmetric synthesis of propargylamines as amino acid surrogates in peptidomimetics.

Authors:  Matthias Wünsch; David Schröder; Tanja Fröhr; Lisa Teichmann; Sebastian Hedwig; Nils Janson; Clara Belu; Jasmin Simon; Shari Heidemeyer; Philipp Holtkamp; Jens Rudlof; Lennard Klemme; Alessa Hinzmann; Beate Neumann; Hans-Georg Stammler; Norbert Sewald
Journal:  Beilstein J Org Chem       Date:  2017-11-15       Impact factor: 2.883

8.  Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.

Authors:  Michal Stark; Yehuda G Assaraf
Journal:  Oncotarget       Date:  2017-07-25

9.  Diastereocontrol in Radical Addition to β-Benzyloxy Hydrazones: Revised Approach to Tubuvaline and Synthesis of O-Benzyltubulysin V Benzyl Ester.

Authors:  Manshu Li; Koushik Banerjee; Gregory K Friestad
Journal:  J Org Chem       Date:  2021-10-12       Impact factor: 4.354

Review 10.  Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.

Authors:  Hao Chen; Zongtao Lin; Kinsie E Arnst; Duane D Miller; Wei Li
Journal:  Molecules       Date:  2017-08-01       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.